Specific mutations in the kinase domain of EGFR render some NSCLC tumors exquisitely dependent on EGFR-mediated signaling for survival and are predictive of response to EGFR-tyrosine kinase inhibitors (TKIs)26-.28 Here, EGFR is linked to non-small cell lung carcinoma.